> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tango's Pancreatic Cancer Combo Shows 82% Response Rate As It Cuts About 14% Of Its Workforce
- URL: https://www.bullished.co/tangos-pancreatic-cancer-combo-shows-82-response-rate-as-it-cuts-about-14-of-its-workforce-86f477c2/
- Published: 2026-10-23T10:51:05.000Z
- Updated: 2026-10-28T17:38:25.000Z
- Description: The biotech plans a front-line Phase 3 trial in the first half of 2027 while narrowing its research to PRMT5 drugs.
- Author: Matteo Parrino
- Tags: SEC Filings, TNGX, Industry: Healthcare

Tango Therapeutics, a clinical-stage biotech that develops targeted cancer medicines, reported an [82% response rate](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526429423/d151613dex991.htm?ref=bullished.co) for vopimetostat plus daraxonrasib in 22 efficacy-evaluable pancreatic cancer patients. In the same [8-K](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526429423/d151613d8k.htm?ref=bullished.co), the company said it will cut roughly 14% of its workforce and drop novel target discovery.

## An 82% response rate, with a dose caveat

The data, presented Friday at the European Society for Medical Oncology congress in Madrid, cover patients with second- or third-line MTAP-deleted, RAS-mutant pancreatic cancer, as of an August 20 data cutoff. Median progression-free survival has not been reached, and 88% of patients were progression-free at nine months. Of the 18 responders, 11 were confirmed partial responses at cutoff; the other 7 were confirmed afterward, the company said.

Safety was clean at the lower dose. Among 25 patients at dose level 1 (200 mg of vopimetostat), 40% had Grade 3 treatment-related adverse events, none had Grade 4 or 5, and there were no dose-limiting toxicities. The higher 250 mg dose was not well tolerated, with 3 dose-limiting toxicities in 2 of 4 patients.

A second combination, vopimetostat with Revolution Medicines' zoldonrasib in MTAP-deleted, KRAS G12D pancreatic cancer, produced a 54% response rate (19 of 35 patients) and a 61% nine-month progression-free rate.

CEO Malte Peters said longer follow-up and more patients confirmed the company's initial June 2026 dataset, and he claimed the results "surpass any published PDAC datasets, even in front-line settings."

## A Phase 3 plan and a narrower company

After talks with the FDA, Tango plans a global, randomized trial in front-line patients, comparing the combination with standard chemotherapy 1:1\. Response rate and progression-free survival are dual primary endpoints, with overall survival a key secondary. The company anticipates starting in the first half of 2027 and says it is pursuing several routes to obtain daraxonrasib supply.

Tango's board approved a strategic reprioritization on October 22 that focuses on PRMT5-targeted therapies, vopimetostat and TNG456, and deprioritizes novel target discovery. Most of the roughly 14% headcount reduction will come from research.

Tango is built around finding drug targets tied to genetic alterations in tumors. Its lead programs are two PRMT5 inhibitors for MTAP-deleted cancers: vopimetostat, and TNG456, which is designed to reach the brain.

## Cash and the calendar

Tango reported about $1.0 billion in cash and investments as of June 30, which it expects to support late-stage pancreatic cancer development. Shares closed at $27.93 on Thursday, up 3.52%, before Friday's results.

Data from vopimetostat monotherapy in non-small cell lung cancer and from TNG456 monotherapy in lung cancer, glioblastoma and other cancers are now expected in January 2027\. A Phase 1/2 combination of vopimetostat with ERAS-0015 is slated to start in the second half of 2026.

Next on the calendar is the January 2027 data from vopimetostat and TNG456 monotherapy trials.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Tango Therapeutics, Inc. (TNGX)](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526429423/d151613d8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d151613dex991.htm — Tango Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526429423/d151613dex991.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d151613dex992.htm — Tango Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001819133/000119312526429423/d151613dex992.htm?ref=bullished.co) — SEC EDGAR
- [Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?](https://finance.yahoo.com/healthcare/articles/tango-therapeutics-tngx-striking-pancreatic-163424109.html?ref=bullished.co) — Yahoo Finance
- [Tango Therapeutics (TNGX) Stock Looks Fully Valued After A 252% Run](https://finance.yahoo.com/markets/stocks/articles/tango-therapeutics-tngx-stock-looks-011632317.html?ref=bullished.co) — Yahoo Finance
- [Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug | Investor's Business Daily](https://www.investors.com/news/technology/tango-therapeutics-stock-revolution-medicines-pancreatic-cancer/?ref=bullished.co) — investors.com
- [Tango Presents Promising Results from Phase 1/2 Study of](https://www.globenewswire.com/news-release/2026/10/23/3387128/0/en/tango-presents-promising-results-from-phase-1-2-study-of-vopimetostat-and-daraxonrasib-in-pancreatic-cancer-and-provides-updates-to-development-strategy.html?ref=bullished.co) — globenewswire.com